Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Higher US reimbursement for VADs (ventricular assist devices):

This article was originally published in Clinica

Executive Summary

The US Centers for Medicare & Medicaid Services (CMS) has recommended the establishment of a new diagnosis related group to cover inpatient ventricular assist device procedures. The proposal, if approved, could mean a 40% rise in reimbursement for the procedure, from the current $38,000 to $53,000, notes Thoratec, the Pleasanton, California developer of the Heartmate left ventricular assist system. The new rule and payment level would take effect on October 1 2002.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel